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A B S T R A C T
Aim: The European Pressure Ulcer Advisory Panel, the Pan Pacific Pressure Injury Alliance, and the National
Pressure Ulcer Advisory Panel are updating the ‘Prevention and Treatment of Pressure Ulcers: Clinical Practice
Guideline’ (CPG) in 2019. The aim of this contribution is to summarize and to discuss the guideline development
protocol for the 2019 update.
Methods: A guideline governance group determines and monitors all steps of the CPG development. An international
survey of consumers will be undertaken to establish consumer needs and interests. Systematic evidence searches in
relevant electronic databases cover the period from July 2013 through August 2018. Risk of bias of included studies
will be assessed by two reviewers using established checklists and an overall strength of evidence assigned to the
cumulative body of evidence. Small working groups review the evidence available for each topic, review and/or draft
the guideline chapters and recommendations and/or good practice statements. Finally, strength of recommendation
grades are assigned. The recommendations are rated based on their importance and their potential to improve
individual patient outcomes using an international formal consensus process.
Discussion: Major methodological advantages of the current revision are a clear distinction between evidence-
based recommendations and good practice statements and strong consumer involvement.
Conclusion: The 2019 guideline update builds on the previous 2014 version to ensure consistency and com-
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T
parability. Methodology changes will improve the guideline quality to increase clarity and to enhance im-
plementation and compliance. The full guideline development protocol can be accessed from the guideline
website (http://www.internationalguideline.com/).
1. Introduction
According to the latest definition of the Institute of Medicine in the
United States ‘Clinical practice guidelines (CPGs) are statements that
include recommendations intended to optimize patient care that are
informed by a systematic review of evidence and an assessment of the
benefits and harms of alternative care options.’ [1]. CPGs are widely
used in many areas of medicine and healthcare to support clinical de-
cision making and to improve patient care and outcomes [2].
One of the first CPGs about pressure injury (PI)1 prevention was
published by the United States Agency for Health Care Policy and Re-
search more than two decades ago [3]. Since then numerous other CPGs
addressing PI prevention and treatment have been published and many
are regularly updated [4–8]. In 2009, the National Pressure Ulcer Ad-
visory Panel (NPUAP) in the United States and the European Pressure
Ulcer Advisory Panel (EPUAP) published the first international CPG for
the prevention and treatment of PIs [9]. The Pan Pacific Pressure Injury
Alliance (PPPIA) joined this successful collaboration and all three or-
ganizations published the first update in 2014 [10,11]. Since publica-
tion, this document has been cited nearly 100 times in Web of Science
(August 2018), the summary version (Quick Reference Guide) has been
downloaded from the International PI CPG homepage (http://www.
internationalguideline.com/) approximately 200,000 times, and trans-
lations into 13 languages are freely available from the EPUAP home-
page (http://www.epuap.org/). This document is due for revision in
2019.
In order to be accurate, reliable, and useful, the development of
CPGs must be standardized and meet methodological quality standards
[1,12–14]. In addition, the science and methods of CPG development
are constantly evolving. For instance, the Grading of Recommendations
Assessment, Development, and Evaluation (GRADE) Working Group
introduced a systematic and explicit approach to develop evidence
based recommendations for CPGs in 2004 [15]. Since then, this fra-
mework was further developed and Evidence-to-Decision frameworks
are now proposed to help guideline developers use evidence in a
structured way to inform guideline recommendations [16,17]. A
number of adapted and alternative guideline development approaches
exist in parallel [18–20], but there is international agreement on key
components of high-quality and trustworthy guidelines [14].
The ‘Prevention and Treatment of Pressure Ulcers: Clinical Practice
Guideline’ of 2014 [10] is due for revision in 2019. The three organi-
zations EPUAP, NPUAP and PPPIA agreed to collaborate and update
this third edition. A guideline governance group (GGG) was formed in
2017 consisting of four representatives of each organization who are
the authors of this manuscript. With the assistance of the methodolo-
gist, Emily Haesler, PhD, this group is responsible for overseeing the
CPG revision process. The CPG development protocol has been adapted
and updated based on experiences from the previous 2014 work,
feedback and discussions about development methods [11,21,22], and
latest methodological developments [17]. The overall objective of the
GGG, on behalf of EPUAP, NPUAP and PPPIA, is to develop a high-
quality and trustworthy PI guideline and to improve PI care worldwide.
The aim of this paper is to summarize and discuss the guideline de-
velopment protocol for the 2019 CPG update. Possible changes to the
guideline development methods described in this protocol will be made
explicit in final guideline document.
2. Clinical Practice Guideline development protocol
The full guideline development protocol for the third edition of the
CPG was finalized in June 2018 and updated in November 2018 [23]. It
can be accessed from the International PI CPG website (http://www.
internationalguideline.com/). This paper is a summary of the full
guideline development protocol and it provides additional background
information and references to justify the current approach.
2.1. Scope and clinical questions
The guideline will briefly summarize the state-of-the-science of PI
aetiology, prevention and treatment and will provide evidence based
recommendations and good clinical practice statements covering PI
prevention and treatment, for all age groups, in all healthcare settings,
irrespective of the medical diagnoses, comorbidities and/or other
health characteristics. The CPG is intended to be used by healthcare
professionals and will provide guidance for caregivers and individuals
at PI risk and those with existing PIs.
PI prevention includes topics such as risk factors and risk assess-
ment, skin and soft tissue assessment and protection. PI treatments will
include topics such as PI assessment and monitoring of healing, pain
management, local wound care strategies, and surgery. Nutrition,
support surfaces and repositioning, which are elements of both PI
prevention and treatment, will also be addressed. Per topic, specific
clinical questions have been developed to guide the evidence searches
and to make recommendations. The complete list of all specific clinical
questions can be seen in Appendix 1 of the full Methodological Protocol
for the CPG (third edition) [23].
In addition to the general recommendations, the unique needs of
specific populations such infants and children, individuals with spinal
cord injuries and individuals with obesity will be addressed. Additional
special populations and healthcare settings include individuals in the
following settings: operating room, palliative care, critical care and
community care settings. However, specific recommendations will only
be provided, if the intervention is unique to this special population.
2.2. Guideline development team
The organizational structure of the CPG development is shown in
Fig. 1. The Member Organizations overseeing development and spon-
soring this update are EPUAP, NPUAP and PPPIA. Four representatives
of each organization form the GGG, which monitors all steps of the CPG
development and dissemination.
Fifteen international Associate Organizations that share the mission
of the GGG support the work and share expertise and perspectives to
complement EPUAP, NPUAP or PPPIA. These organizations, who met
criteria, were selected after a formal application and selection process
by the GGG.
Small Working Groups (SWGs) are formed to review the evidence,
and to review and draft recommendations and guideline content. The
SWG participants are selected based on the principle of equal con-
tribution from the member organizations and representation from at
least one Associate Organization. As well as the participants’ expertise
in the SWG content area and knowledge of research methods.
An experienced guideline methodologist (Dr. Emily Haesler) over-
sees the development process. The methodologist assists the SWG
members in implementing the methodology, appraising and summar-
izing the evidence, revising the 2014 guideline recommendations and
developing new recommendations. The methodologist will also manage
1 The terms pressure ulcer, pressure ulceration and pressure injury are used
synonymously in this text.
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the consumer survey and the confidential consensus voting process for
assigning the Strength of Recommendations. Furthermore, she provides
the link between the GGG, Associate Organizations and the SWGs.
2.3. Conflicts of interest
All individuals engaged in the guideline development (GGG and
SWG members) must be free of major competing interests and must not
have their primary employment in industry. Potential conflicts of in-
terest (COI) are disclosed using a standardized from (see Supplementary
material). A COI arises in any situation in which a group member has a
direct or indirect pecuniary or personal (e.g. academic advancement,
community standing) interest in the way the guideline is developed,
how decisions are made, or how statements and/or recommendations
are framed. Not all financial relationships with industry or other
funding bodies represent true COIs but nevertheless actual or potential
conflicts of interest must be declared to enhance transparency and
credibility of the CPG. The standardized form is based on the re-
commendations of the Guidelines International Network [24] but it is
acknowledged that the assessment of possible non-financial COI is less
detailed. The declarations will be published with the guideline. Po-
tential COI are declared and managed based on an adapted version of
the Guidelines International Network Principles [24]:
(1) Every GGG and SWG member must declare any potential COI ac-
cording to the Disclosure Form (Supplementary material) on an
annual basis during the guideline development.
(2) The COI statements are kept with the Chairpersons of the EPUAP,
NPUAP and PPPIA and the methodologist, and are valid for one
year. Emergent COI during the year must be declared immediately
within the working process or meetings and on an updated COI
form.
(3) Every person (SWG member, GGG members and GGG chairs) with a
‘moderate’ to ‘very high’ COI according to the International
Guidelines Network [24] must:
- not review and/or critically appraise any papers in the area of the
COI
- be excluded from any group discussions, statements and chapter
preparations, and strength of evidence ratings.
Every COI is topic specific. The ‘weight’ of every potential COI will
be evaluated in conjunction with the ‘relevance to topic’ [24].
2.4. Consumer engagement
Consumer engagement is recognized as a requirement for high
quality, international clinical guidelines [14,25–27]. In the context of
this CPG, consumer requirements and goals are detailed in Table 1. In
accordance with international standards [28] consumers (patients, in-
formal caregivers and representatives) will be invited to engage in the
guideline development process and consumers will be recruited to
complete a consumer survey, participate in a Consumer SWG and/or
register as a stakeholder.
2.4.1. Consumer survey
At commencement of the project, an international survey of con-
sumers will be undertaken to establish consumer needs and their in-
terest in outcome measures and inform development of the clinical
questions. Broad consumer input will be sought, with a goal of col-
lecting information from consumers in all geographic regions partici-
pating in the guideline. Information collected via the survey will be
used to review and revise the list of clinical questions, to contribute to
the evidence-to-decision framework, and to develop priorities for con-
sumer education material.
2.4.2. Consumer small working group
A Consumer SWG will be established to review each chapter during
the drafting phase. Member and Associate Organizations will recruit
and nominate consumers from their geographic region, with a goal of
7–10 consumer representatives from each region. Consumer SWG
members will be required to complete COI forms. Consumer SWG
members will be asked to provide feedback using a standardized format
that will include:
Fig. 1. Organisations and stakeholders.
Table 1
Consumer engagement and goals.
Consumer engagement refers to involvement in guideline development from
the following groups:
• patient consumers (i.e. individuals with or at risk of a PI),• informal caregivers (i.e. individuals who provide care in an informal capacity
such as family members, friends or community); and
• consumer stakeholders (i.e. professional consumer representatives).
Goals of consumer engagement:
• promote the relevance of recommendations and guideline content to patient
consumers
• promote patient consumer values and preferences in development of
recommendations and guideline content
• acknowledge and respond to the needs of specific populations groups• respond to consumer education/information needs• promote consumer awareness of the International Guideline
Consumer engagement will be invited through:
• Website invitations.• Invitation via GGG and SWG members.• Invitations to consumer stakeholder groups, Indigenous groups and patient
support network groups (e.g. SCI patient groups) known to GGG members in all
geographic regions.
• Social media.• Recruitment to stakeholder engagement or Consumer SWG will be included in
consumer survey.
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• Sensitivity (language) of terms.
• Relevance to individuals with or at risk of pressure injuries.
• Acceptability of interventions (e.g., preferences, cultural con-
siderations).
• How much of the information the consumer would want to know.
Information provided by the Consumer SWG will be used to review
the presentation of the Guideline, review and revise the recommenda-
tions, develop priorities for consumer education material and con-
tribute to the evidence-to-decision framework.
2.5. Other stakeholders
The process of developing the guideline will be made available to
stakeholders, on the guideline website (http://www.
internationalguideline.com/). Anyone with an interest in PIs, in-
cluding organizations, industry representatives, healthcare profes-
sionals, consumers and informal caregivers, may register as a stake-
holder. In 2014, 698 individuals registered as stakeholders to provide
feedback to the second edition of the guideline.
2.6. Methods
2.6.1. Identifying the evidence
As the guideline builds on a previously published body of evidence,
the evidence search dates for this 2019 update are 1st July 2013
through 31 December 2017. A last update is planned to include evi-
dence published until 31 August 2018. Some SWGs, particularly those
that address evidence in topics newly introduced to the guideline, may
extend the search to ensure previously published literature meeting the
inclusion and exclusion criteria has been represented. Several electronic
databases will be used, such as Medline and Embase, using a sensitive
search strategy. References must meet the following general inclusion
criteria to be considered eligible:
• The articles must be primarily focused on PI prevention, risk as-
sessment, or PI treatment in human subjects.
• The articles must have been published in a peer reviewed journal.
• The articles must report primary research using empirical research
designs.
There will be no language restrictions and as such a pool of trans-
lators is available to assist in the translation process. Synthesized
evidence such as systematic reviews and meta-analysis meeting the
critical domains of the AMSTAR 2 tool [29] will be considered for
comparative discussion.
In the 2014 guideline, a systematic review published by Coleman
et al. [30] was used and updated to summarize the empirical evidence
about PI risk factors. A similar strategy will be used for the Guideline
update, extending Coleman and colleagues search to 31 December 2017
and applying the same methodology.
2.6.2. Risk of bias assessment
The risk of bias of each study will be assessed by two reviewers
using established checklists (Table 2).
Unless otherwise stated in the specific tool design, each criterion on
the critical appraisal checklist will be assessed as being met (Y), not met
(N) not reported/unclear (U), or not applicable (NA). Unless alternate
methods are stated on specific tools, studies will be described as high,
moderate, or low quality using the following criteria:
• High quality studies: fully meet at least 80% of applicable criteria
• Moderate quality studies: fully meet at least 70% of applicable cri-
teria
• Low quality studies: did not fully meet at least 70% of applicable
criteria
2.6.3. Levels of evidence
Within this CPG a distinction will be made between ‘direct’ and
‘indirect’ evidence. Studies of patients with PIs and individuals at PI risk
are considered ‘direct evidence’ and will be required to support an A or
B ‘strength of evidence’ rating (see 2.6.7). Studies in healthy human
subjects, human subjects with other types of chronic wounds, labora-
tory studies using animals, or computational models are regarded as
indirect evidence. Indirect evidence will support recommendations
with a C ‘strength of evidence’ rating, or GGG good practice statements.
The levels of evidence for individual intervention studies will be
assigned to each study containing direct evidence, using a classification
system adapted from The Joanna Briggs Institute [35] (see Table 3).
Diagnostic accuracy studies are studies in which results of index
tests are compared with results from reference standards, sometimes
called gold standard, at the same point in time [38]. Therefore, cross-
sectional designs are needed to establish the concurrent existence of
both index test and reference standard results. A typical example is the
comparison of results of quantitative swab culture (index test) and
quantitative tissue culture (reference standard). Adapted levels of
Table 2
Critical appraisal tools for assessing risk of bias.
Study design Tool Version
Case series Checklist based on a tool reported by Moga, Guo [31] Version published 2012 (accessed
November 2017)
Case control studies Scottish Intercollegiate Guidelines Network (SIGN) checklist for case control studies Version accessed November 2017
Cohort studies SIGN checklist for cohort studies Version accessed November 2017
Cross-sectional/survey studies Checklist derived from the SIGN checklists Developed 2012
Diagnostic studies SIGN checklist for diagnostic studies Version accessed November 2017
Implementation research STaRI checklist [32] PLUS an appropriate checklist to study design when applicable Version published 2017
Qualitative research Critical Appraisal Skills Programme (CASP) Tool Version accessed November 2017
Quality improvement reports Standards for Quality Improvement Reporting Excellence (SQUIRE 2.0) [33] PLUS an
appropriate checklist to study design when applicable
Version published September 2015
Quasi-experiments Checklist adapted from the SIGN checklist for RCTs, and consistent with methodology
reported by Joanna Briggs Institute [34,35].
Version developed 2012
Prognostic designs (excluding those related to
risk)
QUIPS checklist [36] Version published 2013
Randomized controlled trials SIGN checklist for RCTs Version accessed November 2017
Risk factor studies with multivariable
analyses
Methodology outlined by Coleman, Gorecki [37] Version published 2013
Economic evaluations SIGN checklist for economic evaluations, based on the requirements for submission to
the British Medical Journal
Version accessed November 2017
Systematic reviews AMSTAR 2 checklist [29] Version accessed November 2017
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evidence are used for these study designs [39,40] and explained in the
full guideline development protocol [23]. Test accuracy and validity
estimates are only surrogate measures for clinical effectiveness [41].
The clinical effectiveness of diagnostic test procedures can only be
adequately investigated by diagnostic RCTs [39,42]. In case of diag-
nostic or prognostic RCTs the described level of evidence hierarchy of
intervention studies is used.
2.6.4. Data extraction
The full papers of included references will be obtained and made
available to the relevant SWGs on a web-based platform (LineGuide)
that facilitates critical appraisal and data extraction. A data extraction
template will be used to extract relevant data from individual papers,
including study design; description of participants; study groups and
interventions; outcome measures; length of follow up; study results; and
comments and limitations. The technical documents summarizing data
extraction of included studies will be made available at the guideline
website after the guideline has been published.
2.6.5. Developing recommendations
Each SWG will formulate conclusions about the body of available
evidence based on the evidence tables and critical appraisals and levels
of evidence. Evidence tables from previous guideline editions will be
made available to SWGs to ensure the full body of scientific literature is
reviewed. The first draft of recommendations developed by the re-
spective SWGs will be reviewed by the GGG making revisions as ne-
cessary, and then will be additionally reviewed by the Consumer SWG.
To ensure uniformity and internal consistency in the final guideline
recommendations they must comply with the following rule: Each re-
commendation starts with a direct action verb and be a simple, short,
direct, declarative statement, free of jargon.
2.6.6. Terminology
The term ‘individual’ is used to describe the patient, client, resident,
or person with a PI, or at risk for a PI. The terms ‘health professional’
refers to persons with professional qualifications and health profes-
sionals and non-professional healthcare workers who provide formal
healthcare services to the individual, comprise the ‘interprofessional
team’. The roles of professionals/healthcare workers who perform a
given service may vary from country to country based on the laws and
regulations governing healthcare providers. The term ‘informal care-
giver’ is used to describe people providing care to individuals outside
the context of formal healthcare services. This generally refers to family
members and friends.
Medical devices or drugs for PI prevention and treatment such as
dressings, support surfaces, or topical agents available in one country
may not be available in another. Therefore, generic names will be used
when referring to these products. The CPG will not endorse, nor appear
to endorse, the use of any specific products, manufacturers, services or
companies. Consistent with best practice in developing clinical guide-
lines, brand/product names will not be used in recommendation
statements or in the CPG text. Descriptions of products used, and pos-
sible modes of action in the appraised research, will be used as pre-
sented in publications, and more information may be sought from the
manufacturer's product information if required. In evidence tables, full
product and brand names will be used to describe intervention and
control products used in a specific trial on the first time the product/s
are referenced. Thereafter, generic terms (e.g. “the intervention wound
dressing”) will be used.
2.6.7. Strength of evidence ratings
‘Strength of evidence’ ratings will be assigned to recommendations.
This rating identifies the strength of the cumulative body of evidence
supporting each recommendation. Critical appraisals of quality and
levels of evidence for studies in a recommendation's cumulative body of
evidence will be considered in ‘strength of evidence’ ratings. Table 4
outlines the strength of evidence rating system to be used for the 2019
guideline edition (adapted from NHMRC methodology) [27].
The SWGs will summarize the evidence supporting each re-
commendation. An explicit link between the recommendation and
supporting evidence is expected. The strengths and limitations of this
body of evidence will also be clearly described. All recommendations
with a ‘strength of evidence’ rating of A or B will require an explicit
summary of one or more studies conducted with human subjects with
PIs or at risk for PI development. The ‘level of evidence’ for each study
and its quality rating will also be identified.
The GGG good practice statements (Table 4) will be only made
when they are perceived to be necessary. They should help clinicians to
take appropriate actions in areas of uncertainty [43]. The GGG good
practice statements will not be given a strength of recommendation,
consistent with current best practice in guideline development [43].
Evidence gaps will be explicitly identified and will serve as an agenda
Table 3
Levels of evidence for intervention studies [35].
Level 1 Experimental Designs
• Randomized trial
Level 2 Quasi-experimental design
• Prospectively controlled study design• Pre-test post-test or historic/retrospective control group study
Level 3 Observational-analytical designs
• Cohort study with or without control group• Case-controlled study
Level 4 Observational-descriptive studies (no control)
• Observational study with no control group• Cross-sectional study• Case series (n = 10+)
Level 5 Indirect evidence: studies in normal human subjects, human subjects
with other types of chronic wounds, laboratory studies using animals,
or computational models
Table 4
Strength of evidence rating for each recommendation (adapted from NHMRC) [27].
A • More than one high quality Level I study providing direct evidence• Consistent body of evidence
B1 • Level 1 studies of moderate or low quality providing direct evidence• Level 2 studies of high or moderate quality providing direct evidence• Most studies have consistent outcomes and inconsistencies can be explained
B2 • Level 2 studies of low quality providing direct evidence• Level 3 or 4 studies (regardless of quality) providing direct evidence• Most studies have consistent outcomes and inconsistencies can be explained
C • Level 5 studies (indirect evidence) e.g., studies in healthy human subjects, humans with other types of chronic wounds, animal models• A body of evidence with inconsistencies that cannot be explained, reflecting genuine uncertainty surrounding the topic
Good practice statement • Statements by the GGG that are not supported by a body of evidence as listed above but considered significant for clinical practice.
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for future research efforts.
2.6.8. Strength of recommendations
The ‘strength of evidence’ ratings identify the strength of cumulative
evidence across studies supporting the recommendation. In addition,
‘strength of recommendation’ grades are assigned (Table 5). The re-
commendations are rated based on their importance and their potential
to improve individual patient outcomes. The ‘strength of re-
commendation’ is the extent to which a health professional can be
confident that adherence to the recommendation will do more good
than harm. The grading of importance is not necessarily related to the
strength of internal or external evidence. The overall aim is to help
health professionals to prioritize interventions. The following points
will be considered when assigning the strength of recommendation
[44–48]:
• The balance between benefits and harms. The larger the difference
between both, the higher the likelihood for giving a strong re-
commendation.
• The overall quality of evidence across all studies upon which the
recommendation is based. The higher the quality, the higher the
likelihood that a strong recommendation is warranted.
• Successful translation of the evidence into practice in specific clin-
ical settings or populations of interest.
• The higher the financial costs of an intervention, the greater the
resources consumed, the lower the likelihood that a strong re-
commendation is warranted, unless cost effectiveness can be de-
monstrated.
Besides overall methodological study quality and the balance be-
tween risks, harms and resources, in diagnostic accuracy and prognostic
recommendations the following additional question will be considered
for recommendation development:
• How strong is the confidence that estimated probabilities improve
clinical decision making, treatment decisions and subsequent pa-
tient outcomes? [41,42,49].
The ‘strength of recommendation’ grades will be achieved via a
formal consensus process using an adapted-GRADE grid. In this con-
sensus process, all SWG and the GGG members are invited to take part,
each voting on every recommendation in the guideline. The consensus
voting process will be conducted on the website, with each team
member provided with a unique identification. The participants will be
required to confirm their understanding of the procedure before com-
mencing.
The process will be facilitated using an evidence-to-decision fra-
mework that will be finalized by the GGG. An evidence-to-decision
framework presents relative pros and cons for interventions and ensures
individuals voting on recommendations do so with a more complete
understanding of the evidence and implications of recommendations.
For each recommendation to be evaluated using the adapted-GRADE
process, voters will be presented with a tabulated summary of the
evidence relevant to questions about desirable and undesirable antici-
pated effects, the overall certainty of evidence, resource requirements,
feasibility of implementation, and values of consumers.
After reviewing the evidence-to-decision table, voters will be asked
to select a ‘strength of recommendation’ grade from the options pre-
sented in Table 5 and an additional option to abstain from voting (with
reason provided). Votes will be recorded and calculated using a soft-
ware program designed for the purpose. Participants will be able to
nominate a ‘strength of recommendation’ for as few, or as many re-
commendations as they prefer, but will be strongly encouraged to vote
on all recommendations.
Rules for determining ‘strength of evidence’ were determined based
on previous applications of the adapted GRADE process, and a desire to
obtain significant consensus. Determination of the final ‘strength of
recommendation’ will be made according to the following rules:
• To achieve a strong positive (do it) or strong negative (don't do it)
recommendation, 100% of votes must be cast in the same direction
(positive or negative), with at least 70% voting for a strong re-
commendation, and 0% voting in the opposite direction.
• To achieve a weak positive (probably do it) or weak negative
(probably don't do it) recommendation, at least 70% of votes must
cast in the same direction (positive or negative), and less than 20%
voting in the opposite direction.
• Any other combination of voting results in ‘no specific re-
commendation’.
As can be seen in Table 5, the thumb sign used in the 2014 CPG has
been replaced by arrows. From a conceptual point of view it does not
matter whether symbols, letters or numbers are used [50]. However,
this decision has been made to avoid any potential cultural issues.
3. Discussion
The EPUAP, NPUAP and PPPIA are currently developing the third
edition of the International CPG for the prevention and treatment of PIs
according to the methods described in this protocol. Overall, the de-
velopment is similar to the previous version to ensure consistency and
comparability. However, some changes were considered necessary to
Table 5
Five types of recommendations [15,45,46].
Recommendation Symbol Description Implications
Do it: Strong recommendation for an intervention ↑↑ Indicates a judgment that most well
informed people would make.
For patient consumers—Most people would want the recommended
course of action and only a small proportion would not.
For health professionals—Most people should receive the intervention.
If health professionals choose not to follow the recommendation,
they should document their rationale.
For quality monitors—Adherence to this recommendation could be
used as a quality criterion or performance indicator.
Don't do it: Strong recommendation against an
intervention
↓↓
Probably do it: Conditional recommendation for
using an intervention
↑ Indicates a judgment that a majority of
well informed people would make, but a
substantial minority would not.
For patient consumers—Most people would want the suggested course
of action, but many would not.
For health professionals —Examine, and be prepared to discuss, the
evidence with patients, as well as their values and preferences.
For quality monitors—Clinicians’ discussion and consideration of pros
and cons of the intervention, and documentation of discussion, could
be used as a quality indicator.
Probably don't do it: Conditional recommendation
against using an intervention
↓
No specific recommendation: Conditional
recommendation for either the intervention or
the comparison
↔ Trade-offs between risk and benefit
unclear or lack of agreement between
voting participants.
The advantages and disadvantages are equivalent; and/or the target
population has not been identified; and/or there is insufficient
evidence on which to formulate a ‘strength of recommendation’.
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improve the CPG quality and to make this document more powerful.
3.1. Strength of evidence ratings and good practice statements
In the 2014 CPG a slightly different strength of evidence hierarchy was
used. Expert opinion was considered as one source of evidence to support
the lowest strength of evidence level C, for the 2019 update, expert opi-
nion has been identified more transparently. The GGG believes that expert
opinion is of major importance to inform clinical practice, because sci-
entific evidence is either indirect or widely missing in many different areas
of PI prevention and treatment [11]. However, in a strict sense, formal
strength of evidence and strength of recommendation ratings are in-
appropriate for expert opinions [43]. Instead, good practice statements
will be developed. These statements typically represent situations in which
evidence is missing but the GGG considers this significant for clinical
practice. At the same time good practice statements will be used only
when they are necessary, that is, without such a statement, clinicians
might fail to take the appropriate action [43].
This adapted methodology will have several advantages: the overall
number of guideline recommendations will be reduced, enhancing the
clarity and readability of the document. A clearer distinction will be
made between evidence based formal guideline recommendations and
crucial best practice statements. The reduction of trivial statements,
length and complexity is considered as one measure to enhance com-
pliance with this guideline [51]. Because of the changes to metho-
dology, the ratings given to studies in previous editions of the CPG will
also be reviewed. For recommendations supported by direct evidence,
the addition of evidence-to-decision frameworks will more explicitly
link the evidence to decisions regarding evidence-based based re-
commendations.
3.2. Special populations
The focus on specific populations is important and takes the special
PI risk and treatment challenges for each group into account. However,
in the 2014 edition this led to a number of repetitions of guideline
recommendations in the special populations’ chapters. The GGG be-
lieves that key PI preventive and treatment interventions are similar
across populations. Therefore, attention will be paid in this edition to
avoiding unnecessary repetitions, and to develop only those re-
commendations and/or good practice statements, that are unique to the
given populations. This, will reduce the overall number of re-
commendations and make this edition of the CPG more concise. The
needs of individuals in community settings will be examined for the
first time in the 2019 Guideline.
3.3. Consumer engagement
Insufficient consumer engagement was a weakness in the 2014 CPG.
Therefore, several measures are implemented to engage consumers via
various channels. The consumer survey is available July 2018 through
October 2018; with over 1200 respondents to date. In addition to in-
forming the clinical questions and the guideline content, the results of
this survey will be a major source for directing future PI research and
development of patient consumer resources.
3.4. Dissemination and implementation
In addition to the hard copy version, the CPG will be disseminated
as an electronic version as a downloadable pdf. The Quick Reference
Guide (QRG) has been available in both paper and electronic forms
since 2009. As with previous versions of the Guideline the GGG will
work with individuals willing to translate the Guideline into languages
other than English. Implementation tools and guides will be developed
by the GGG and sponsoring organizations in order to meet the cultural
and unique practice needs of different regions of the world.
4. Conclusions
Based on the previous experiences and latest methodological de-
velopments, the GGG and methodologist has improved the CPG devel-
opment methods as described in this protocol. This will result in an
enhanced quality CPG which is expected to be implemented more
widely than previously, improving the quality of PI prevention and
treatment worldwide.
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